Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis

Summary

This study has a randomized, double-blind, placebo-controlled design to assess the efficacy, pharmacodynamics and safety/tolerability of omiganan in patients with mild to moderate atopic dermatitis when applied BID to all atopic dermatitis lesions.

Timeline

Start

2017-03-08

Primary completion

2017-12-20

Completion

2017-12-20

Drugs

Indications